Press

Filament Health and Psyence Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

Dec 15 • 3 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, today announced the conclusion of a royalty-bearing, worldwide commercial licensing agreement. The agreement grants Psyence the…

Mind Cure Enters Into Binding Letter of Intent with LNG Energy Group

Dec 15 • 6 min read

Mind Cure Health Inc. (CSE: MCUR | OTCQB: MCURF | FRA: 6MH) today announced that it has signed a binding Letter of Intent with LNG Energy Group Inc. pursuant to which the Company will acquire all of the issued and outstanding securities in the capital of LNG Energy by way of a business combination transaction….

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Dec 15 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug Administration (“U.S. FDA”) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF). Ifenprodil is the sole active ingredient in…

Mindbloom Announces Rollout of Ketamine Telehealth Employee Benefits Program with Kennedy Care, 15Five

Dec 14 • 3 min read

Mindbloom, the world’s largest provider of ketamine therapy, announced Wednesday the launch of a new employee benefits partnership with Kennedy Care, a leader in home care services across Michigan and Northern Ohio. As of November, Kennedy Care employees can access at-home ketamine therapy through Mindbloom. “I’m beyond thrilled that Mindbloom has agreed to work with my…

Core One Labs : Subsidiary Vocan Biotechnologies Achieves Development Milestones

Dec 14 • 2 min read

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6, WKN: A3CSSU) the Company is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc., has successfully achieved two critical development milestones, the successful synthesis of psilocybin and the filing of a patent application for the process with the United States Patent and Trademark Office. Achievement of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441